102 related articles for article (PubMed ID: 24111910)
1. Editorial: new developments in the search for agents to treat tuberculosis.
Boechat N
Curr Top Med Chem; 2013; 13(22):2807. PubMed ID: 24111910
[No Abstract] [Full Text] [Related]
2. Novel 1,2,3-triazole derivatives for use against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain.
Boechat N; Ferreira VF; Ferreira SB; de Lourdes G Ferreira M; de C da Silva F; Bastos MM; Dos S Costa M; Lourenço MC; Pinto AC; Krettli AU; Aguiar AC; Teixeira BM; da Silva NV; Martins PR; Bezerra FA; Camilo AL; da Silva GP; Costa CC
J Med Chem; 2011 Sep; 54(17):5988-99. PubMed ID: 21776985
[TBL] [Abstract][Full Text] [Related]
3. Comparative cytotoxic and anti-tuberculosis activity of Aplysina caissara marine sponge crude extracts.
Azevedo LG; Muccillo-Baisch AL; Filgueira Dde M; Boyle RT; Ramos DF; Soares AD; Lerner C; Silva PA; Trindade GS
Comp Biochem Physiol C Toxicol Pharmacol; 2008 Jan; 147(1):36-42. PubMed ID: 17826358
[TBL] [Abstract][Full Text] [Related]
4. Efficient synthesis and in vitro antitubercular activity of 1,2,3-triazoles as inhibitors of Mycobacterium tuberculosis.
Shanmugavelan P; Nagarajan S; Sathishkumar M; Ponnuswamy A; Yogeeswari P; Sriram D
Bioorg Med Chem Lett; 2011 Dec; 21(24):7273-6. PubMed ID: 22061642
[TBL] [Abstract][Full Text] [Related]
5. In vitro advanced antimycobacterial screening of isoniazid-related hydrazones, hydrazides and cyanoboranes: part 14.
Maccari R; Ottanà R; Vigorita MG
Bioorg Med Chem Lett; 2005 May; 15(10):2509-13. PubMed ID: 15863306
[TBL] [Abstract][Full Text] [Related]
6. Application of Huisgen (3+2) cycloaddition reaction: synthesis of 1-(2,3-dihydrobenzofuran-2-yl-methyl [1,2,3]-triazoles and their antitubercular evaluations.
Tripathi RP; Yadav AK; Ajay A; Bisht SS; Chaturvedi V; Sinha SK
Eur J Med Chem; 2010 Jan; 45(1):142-8. PubMed ID: 19846238
[TBL] [Abstract][Full Text] [Related]
7. Potential tuberculostatic agents: micelle-forming copolymer poly(ethylene glycol)-poly(aspartic acid) prodrug with isoniazid.
Silva M; Lara AS; Leite CQ; Ferreira EI
Arch Pharm (Weinheim); 2001 Jun; 334(6):189-93. PubMed ID: 11475908
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic investigation of the oxidation of hydrazides: implications for the activation of the TB drug isoniazid.
Amos RI; Gourlay BS; Yates BF; Schiesser CH; Lewis TW; Smith JA
Org Biomol Chem; 2013 Jan; 11(1):170-6. PubMed ID: 23165368
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9.
Bottari B; Maccari R; Monforte F; Ottanà R; Rotondo E; Vigorita MG
Bioorg Med Chem Lett; 2000 Apr; 10(7):657-60. PubMed ID: 10762047
[TBL] [Abstract][Full Text] [Related]
10. Development of a three component complex to increase isoniazid efficacy against isoniazid resistant and nonresistant Mycobacterium tuberculosis.
Manning T; Plummer S; Baker T; Wylie G; Clingenpeel AC; Phillips D
Bioorg Med Chem Lett; 2015 Oct; 25(20):4621-7. PubMed ID: 26341133
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and mycobactericidal properties of metal complexes of isonicotinoyldithiocarbazic acid.
Kanwar SS; Lumba K; Gupta SK; Katoch VM; Singh P; Mishra AK; Kalia SB
Biotechnol Lett; 2008 Apr; 30(4):677-80. PubMed ID: 18026843
[TBL] [Abstract][Full Text] [Related]
12. [Hixozide, a novel combined antituberculosis preparation].
Glushkov RG; Sokolova GB
Antibiot Khimioter; 2008; 53(5-6):11-3. PubMed ID: 19069176
[No Abstract] [Full Text] [Related]
13. Transmission of isoniazid-resistant tuberculosis.
Borgdorff MW
J Infect Dis; 2004 Aug; 190(3):650; author reply 650-1. PubMed ID: 15243944
[No Abstract] [Full Text] [Related]
14. Rational design, synthesis and antitubercular evaluation of novel 2-(trifluoromethyl)phenothiazine-[1,2,3]triazole hybrids.
Addla D; Jallapally A; Gurram D; Yogeeswari P; Sriram D; Kantevari S
Bioorg Med Chem Lett; 2014 Jan; 24(1):233-6. PubMed ID: 24314670
[TBL] [Abstract][Full Text] [Related]
15. New series of isoniazid hydrazones linked with electron-withdrawing substituents.
Vavříková E; Polanc S; Kočevar M; Košmrlj J; Horváti K; Bosze S; Stolaříková J; Imramovský A; Vinšová J
Eur J Med Chem; 2011 Dec; 46(12):5902-9. PubMed ID: 22018878
[TBL] [Abstract][Full Text] [Related]
16. Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains.
Férriz JM; Vávrová K; Kunc F; Imramovský A; Stolaríková J; Vavríková E; Vinsová J
Bioorg Med Chem; 2010 Feb; 18(3):1054-61. PubMed ID: 20060303
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation.
Kumar D; Beena ; Khare G; Kidwai S; Tyagi AK; Singh R; Rawat DS
Eur J Med Chem; 2014 Jun; 81():301-13. PubMed ID: 24852277
[TBL] [Abstract][Full Text] [Related]
18. [The mechanism of action of isoniazid. A chemical model of activation].
Bernadou J; Nguyen M; Meunier B
Ann Pharm Fr; 2001 Sep; 59(5):331-7. PubMed ID: 11787427
[TBL] [Abstract][Full Text] [Related]
19. A convenient synthesis and screening of benzosuberone bearing 1,2,3-triazoles against Mycobacterium tuberculosis.
Sajja Y; Vanguru S; Jilla L; Vulupala HR; Bantu R; Yogeswari P; Sriram D; Nagarapu L
Bioorg Med Chem Lett; 2016 Sep; 26(17):4292-5. PubMed ID: 27476139
[TBL] [Abstract][Full Text] [Related]
20. The molecular basis of isoniazid resistance in Mycobacterium tuberculosis.
Heym B; Saint-Joanis B; Cole ST
Tuber Lung Dis; 1999; 79(4):267-71. PubMed ID: 10692996
[No Abstract] [Full Text] [Related]
[Next] [New Search]
